

The prognostic *IDH1*^{R132} mutation is associated with reduced NADP⁺-dependent IDH activity in glioblastoma

Fonnet E. Bleeker · Nadia A. Atai · Simona Lamba · Ard Jonker ·
Denise Rijkeboer · Klazien S. Bosch · Wikky Tigchelaar · Dirk Troost ·
W. Peter Vandertop · Alberto Bardelli · Cornelis J. F. Van Noorden

Received: 17 December 2009 / Revised: 18 January 2010 / Accepted: 19 January 2010 / Published online: 4 February 2010
© The Author(s) 2010. This article is published with open access at Springerlink.com

Abstract Somatic mutations in the isocitrate dehydrogenase 1 gene (*IDH1*) occur at high frequency in gliomas and seem to be a prognostic factor for survival in glioblastoma patients. In our set of 98 glioblastoma patients, *IDH1*^{R132} mutations were associated with improved survival of 1 year on average, after correcting for age and other variables with Cox proportional hazards models. Patients with *IDH1* mutations were on average 17 years younger than patients without mutation. Mutated IDH1 has a gain of function to produce 2-hydroxyglutarate by NADPH-dependent reduction of α -ketoglutarate, but it is unknown whether NADPH production in gliomas is affected by *IDH1* mutations. We

assessed the effect of *IDH1*^{R132} mutations on IDH-mediated NADPH production in glioblastomas in situ. Metabolic mapping and image analysis was applied to 51 glioblastoma samples of which 16 carried an *IDH1*^{R132} mutation. NADP⁺-dependent IDH activity was determined in comparison with activity of NAD⁺-dependent IDH and all other NADPH-producing dehydrogenases, glucose-6-phosphate dehydrogenase, 6-phosphogluconate dehydrogenase, malate dehydrogenase, and hexose-6-phosphate dehydrogenase. The occurrence of *IDH1* mutations correlated with approx. twofold diminished NADP⁺-dependent IDH activity, whereas activity of NAD⁺-dependent IDH and the other NADP⁺-dependent dehydrogenases was not affected in situ in glioblastoma. The total NADPH production capacity in glioblastoma was provided for 65% by IDH activity and the occurrence of *IDH1*^{R132} mutation reduced this capacity by 38%. It is concluded that NADPH production is hampered in glioblastoma with *IDH1*^{R132} mutation. Moreover, mutated IDH1 consumes rather than produces NADPH, thus likely lowering NADPH levels even further. The low NADPH levels may sensitize glioblastoma to irradiation and chemotherapy, thus explaining the prolonged survival of patients with mutated glioblastoma.

F. E. Bleeker and N. A. Atai contributed equally to the study.

N. A. Atai · A. Jonker · D. Rijkeboer · K. S. Bosch ·
W. Tigchelaar · C. J. F. Van Noorden (✉)
Department of Cell Biology and Histology,
Academic Medical Center, University of Amsterdam,
Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands
e-mail: c.j.vannoorden@amc.uva.nl

F. E. Bleeker · W. P. Vandertop
Neurosurgical Center Amsterdam, Academic Medical Center,
University of Amsterdam, Amsterdam, The Netherlands

F. E. Bleeker · S. Lamba · A. Bardelli
Laboratory of Molecular Genetics,
Institute for Cancer Research and Treatment,
University of Torino Medical School, Candiolo (TO), Italy

D. Troost
Department of Neuropathology, Academic Medical Center,
University of Amsterdam, Amsterdam, The Netherlands

A. Bardelli
FIRC Institute of Molecular Oncology, Milan, Italy

Keywords IDH1 · IDH2 · Mutation · Glioblastoma ·
IDH activity · NADPH · Metabolic mapping

Introduction

Primary and secondary glioblastomas display somatic mutations in the *IDH1* gene. The mutation is relatively rare in primary glioblastoma (approx. 5% of the tumors harbor the mutation) and frequent in secondary glioblastoma (70–80% of the tumors carry the mutation [3, 5, 10, 12, 19, 21,

24, 25, 32–34, 36]). *IDH1* encodes for NADP⁺-dependent isocitrate dehydrogenase 1, which can be found in cytoplasm, peroxisomes [9] and endoplasmic reticulum [18] and belongs to a gene family encompassing five members [9, 18]. Wild-type IDH1 catalyzes the oxidative decarboxylation of isocitrate to α -ketoglutarate [15] with concomitant production of NADPH. Mutations in *IDH1* are tumor specific and have so far been detected in various types of gliomas, especially in those histologically classified as low-grade gliomas and secondary glioblastoma [3, 5, 10, 12, 19, 21, 24, 32, 33, 36] and in a subset of acute myeloid leukemia [17]. Mutations affecting the isocitrate dehydrogenase 2 gene (*IDH2*), another NADP⁺-dependent IDH localized in mitochondria, have also been described in gliomas although at lower frequency [10, 25, 36]. The other three members of the IDH family are exclusively localized in mitochondria, depend on NAD⁺ for their enzymatic activity and play a relevant role in the Krebs cycle [37]. These NAD⁺-dependent IDHs are not known to be mutated in relation to gliomagenesis.

The mutational profile of *IDH1* and *IDH2* is peculiar as the mutations affect only single evolutionarily conserved residues (arginines R132 and R172, respectively). The arginines are localized in the substrate binding site of the isozymes, where hydrophilic interactions between the arginine and both α - and β -carboxylate of isocitrate are formed [35]. Interestingly, from a genetic perspective the pattern of *IDH1* mutations is consistent with a gain of function (such as those occurring in oncogenes). However, it has been shown that the mutations inactivate the standard enzymatic activity of IDH1 and IDH2 [12, 36]. As a consequence, α -ketoglutarate levels are reduced when IDH1 is mutated. α -Ketoglutarate in the cytoplasm initiates oxygen-dependent degradation of hypoxia-inducible factor subunit HIF-1 α [22, 27, 38]. Thus, decreased cytoplasmic levels of α -ketoglutarate increase levels of HIF-1 α and the heterodimer HIF-1 consisting of HIF-1 α and HIF-1 β is transported into the nucleus for transcriptional activity [11, 22, 27]. HIF-1 is the master switch of cellular adaptation to low oxygen tension and induces transcription of genes involved in angiogenesis, cell motility and invasion and energy metabolism [11]. Furthermore, a recent report has shown that mutated IDH1 does not convert isocitrate and NADP⁺ into α -ketoglutarate and NADPH but rather has a gain of function enabling IDH1 to convert α -ketoglutarate and NADPH into 2-hydroxyglutarate and NADP⁺ [8]. It was shown that glioma samples with the IDH1 mutation contained high 2-hydroxyglutarate levels [8]. Interestingly, in patients with 2-hydroxyglutarate dehydrogenase deficiency, 2-hydroxyglutarate accumulation is associated with a higher risk of malignant brain tumors [1].

How the *IDH1*^{R132} mutations affect NADPH production in human tumors is presently unknown and is a matter of

debate [22, 27]. NADPH plays an important role in detoxification processes and scavenging of oxygen radicals [14] and thus is a protective compound in cancer cells under stress during irradiation or chemotherapy.

In the present study, we correlated the occurrence of *IDH1*^{R132} mutations with overall survival of glioblastoma patients using multivariable analysis. Furthermore, we applied metabolic mapping and image analysis to assess the NADP⁺-dependent and NAD⁺-dependent enzymatic activity of IDH in comparison with the activity of all other NADPH-producing dehydrogenases [30] in glioblastoma in situ. This strategy was then exploited to correlate the *IDH1* mutational status with its enzymatic activity.

Materials and methods

Tumor samples, isolation of DNA, PCR, sequencing and mutation analysis

DNA samples of 109 frozen glioblastomas, for which the mutational status of *IDH1* was previously determined [5], were obtained from the tumor bank maintained by the Departments of Neurosurgery and Neuropathology at the Academic Medical Center (Amsterdam, The Netherlands). In the present study, these glioblastoma samples were analyzed for *IDH2* mutations, and a subset of these samples was used for survival analysis and enzyme activity. Use of material was waived by our local ethics committee, as it fell under the Dutch Code of proper secondary use of human tissue. The research was performed on ‘waste’ material, stored in a coded fashion.

Tumor samples were included only if at least 80% of the sample consisted of cancer cells, as verified by H&E staining. Genomic DNA was isolated as previously described [2]. PCR, sequencing and mutation analysis details have been described previously [5].

Glioblastoma patient data

A retrospective survival analysis was performed for 98 glioblastoma patients with known follow-up. Both primary (85) and secondary glioblastoma (13), but no recurrent glioblastoma patients were included. These patients underwent brain surgery at the AMC between 1988 and 2006 and were selected, when enough tissue was available to perform the experiments described. Patient characteristics are displayed in Table 1. The primary end point of this analysis was overall survival, calculated as time from surgery to death. Events were censored if the patient was alive at the time of last follow-up. Follow-up for patients ranged from 15 to 2,722 days. The median overall survival was 262 days; the 2-year survival rate was 15%. Patients

Table 1 Baseline characteristics of 98 glioblastoma patients included in survival analysis

		IDH1 wt	IDH1 mutated	<i>P</i> value
Samples		80	18	
Tumor occurrence	Primary glioblastoma	75 (95%)	10 (56%)	<0.001
	Secondary glioblastoma	5 (5%)	8 (44%)	
Age (years)		58 (27–80)	41 (28–62)	<0.001
Gender	M	44 (55%)	9 (50%)	0.704
	F	36 (45%)	9 (50%)	
KPS		75 (50–90)	76 (50–90)	0.813
Surgical procedure	Biopsy or radical resection	34 (43%)	7 (39%)	0.782
	Gross total removal	46 (57%)	11(61%)	
Irradiation dosage (Gy)		39 (0–78)	48 (0–66)	0.193
Other therapy	No additional therapy	53 (66%)	8 (44%)	0.086
	Additional therapy	27 (34%)	10 (56%)	

Data are mean (range) or number (%)

KPS Karnofsky performance score, IDH1 isocitrate dehydrogenase 1, wt non-mutated

have been treated with different regimens either in trials or with standard protocols. Other therapies in addition to irradiation included chemoradiation (radiotherapy with concomitant and adjuvant temodal), brachytherapy, gliadel, PCV, temodal, MTX and nicotinamine (an enhancer during irradiation).

Metabolic mapping

Glioblastoma and normal brain tissue were snap-frozen in liquid nitrogen in the operating room, and stored at -80°C until used. Normal brain sections contained both grey and white matter. Six- μm -thick cryostat sections were cut at -25°C on a HM560 cryostat (MICROM, Walldorf, Germany), picked up on glass slides, and stored at -80°C until used [30]. Cryostat sections of glioblastoma tissue were allowed to dry at room temperature for 5 min and were then incubated for the demonstration of IDH, G6PDH, 6PGDH, MDH and H6PDH activity [26, 29]. Incubation media contained 18% polyvinyl alcohol (PVA, average molecular mass 70,000–100,000; Sigma, St. Louis, MO) in 0.1 M phosphate buffer, pH 7.4, 0.32 mM 1-methoxyphenazine methosulfate (Serva, Heidelberg, Germany), 5 mM sodium azide, 5 mM MgCl_2 , 5 mM nitro BT (Sigma), and either 20 mM D,L-isocitrate (Sigma) or 10 mM glucose-6-phosphate (Serva), or 10 mM 6-phosphogluconate (Sigma), or 100 mM malate (Serva), or 10 mM galactose-6-phosphate (Sigma) to demonstrate activity of IDH, G6PDH, 6PGDH, MDH, or H6PDH, respectively. For NADP⁺-dependent dehydrogenases, 0.8 mM NADP⁺ (Roche, Mannheim, Germany) was used as co-enzyme, whereas for the NAD⁺-dependent IDH activity, 4 mM NAD⁺ (Roche) was used. The concentrations of the substrates and co-enzymes in the incubation media were sufficiently high to ensure maximum velocity (V_{max}) of the enzyme activities [26, 28]. Negative control reactions were performed in the absence of substrate [6].

The media were freshly prepared just before incubation and nitro BT was added after being dissolved in a heated mixture of dimethylformamide and ethanol (final dilution of each solvent in the medium was 2% v/v). For the demonstration of both NAD⁺- and NADP⁺-dependent IDH activity, sections were incubated for 45 min at 37°C . For activity of G6PDH, 6PGDH, MDH and H6PDH sections were incubated for 30, 10, 45, and 45 min, respectively at 37°C . Sections were then rinsed with hot phosphate buffer (0.1 M, pH 5.3, 65°C) to remove the incubation medium and to immediately stop the reaction. Afterwards, sections were embedded in glycerol jelly.

Image analysis

The final reaction product of dehydrogenase activity (nitro BT-formazan) was analyzed with the use of quantitative image analysis, using a Vanox-T photomicroscope with a 10 \times objective (Olympus, Tokyo, Japan) and a CFW-1312M 1,360 \times 1,024 pixel 10-bit monochrome FireWire camera (Scion, Tucson, AZ) mounted on the front port of the Vanox using adapting optics. Sections were illuminated with white light that was filtered by a monochromatic filter of 585 nm and an infrared blocking filter [7] to correctly measure the absorbance of both mono- and di-formazans [26, 29]. Absorbance calibration of the images was performed with the use of a calibrated 10-step density tablet (Stouffer, South Bend, IN). After measuring the step tablet, known absorbance values were related to measured grey values using the built-in calibration function of ImageJ, using the Rodbard function. Density calibrated images were recorded in one single run and stored on disk for analysis. The resolution used prevented distributional errors [7]. All settings were maintained throughout the recording session and at the end of the session verified against the step tablet values. Software used for capturing was swf-image, a Scion proprietary camera driver, as an extension to the image

processing application ImageJ, developed by Wayne Rasband [23]. ObjectJ, a plugin for non-destructive image marking and result linking developed by Norbert Vischer and Stelian Nastase at the Department of Biology of the University of Amsterdam [31], was used to indicate regions of interest (ROI) that were measured. Using the ObjectJ plugin, mean absorbance values within the ROI were collected from the test reaction and the control reaction, allowing calculation of specific activity of IDHs, G6PDH, 6PGDH, MDH and H6PDH, respectively [29]. Activity was expressed as micromoles NADPH produced per milliliter of tissue/min. The use of ObjectJ allows a retrospective quality control study of areas measured.

Statistical analysis

Statistical processing of data was performed using Excel 2002 (Microsoft, San Jose, CA) and SPSS 16.02 for Windows (SPSS, Chicago, IL). Associations between the different dehydrogenase activities and *IDH1* mutations were assessed by *t* test. The association between *IDH1* mutations or NADP⁺-dependent IDH activity and survival time was tested with Cox proportional hazard models. After the individual tests, factors with *P* values less than 0.10 were included in the multivariable Cox model to determine the factors associated with survival time (Table 2).

Results

Mutational profiling of *IDH1* and *IDH2* in glioblastoma

A panel of 109 glioblastoma (94 primary and 15 secondary) for which the prevalence of *IDH1*^{R132} mutations had already been assessed [5] was also analyzed for *IDH2* mutations. No somatic *IDH2* mutations were observed in this set of tumors.

Mutation at *IDH1*^{R132} is an independent prognostic factor for improved survival in glioblastoma patients

In a subset of 98 glioblastoma with known follow-up, the overall survival of both primary and secondary glioblastoma was increased for patients whose tumors carried an *IDH1* mutation (*P* = 0.002, log rank test). Moreover, patients without mutation were on average 58 years old, whereas patients with mutation were 41 years old. When corrected for age, Karnofsky performance status (KPS), extent of surgery, received dosage of radiotherapy, additional chemotherapy or treatment other than radiotherapy (Table 2), the mutational status of *IDH1*^{R132} was a strong independent prognostic factor for improved overall survival (*P* < 0.001; Fig. 1; Table 2). This significant association indicates that the presence of *IDH1* mutation correlates with an improved prognosis for glioblastoma patients which is in agreement with other studies [19, 24, 25, 34].

IDH1^{R132} mutations are associated with diminished in situ NADP⁺-dependent IDH activity in glioblastoma cells

Activity of NADP⁺-dependent IDH was determined in glioblastoma cryostat sections of tumor samples of 51 glioblastoma patients (Fig. 2) to evaluate whether and to what extent *IDH1* mutations affect the metabolic status of glioblastoma cells. These 51 tumor samples included 15 tumor samples mutated at *IDH1*^{R132}, of these, 12 contained the R132H mutation, two the R132C mutation and one sample the R132G mutation (Fig. 3b). Activity was heterogeneous within tumor samples (Fig. 2c). As this could be associated with the presence of necrosis, the regions analyzed were 'validated' by H&E staining of adjacent sections to contain vital tumor tissue (Fig. 2b, d). Representative areas with the most uniform activity of each

Table 2 Univariate and multivariable association between 98 glioblastoma patient characteristics and overall survival

	Univariate Cox regression			Multivariate Cox regression		
	HR	95% CI	<i>P</i>	HR	95% CI	<i>P</i>
Age (per year)	1.028	1.012–1.045	0.001	1.010	0.990–1.031	0.328
Sex	1.114	0.728–1.799	0.559	*	*	*
KPS (per 10 points)	0.969	0.949–0.989	0.002	0.974	0.954–0.995	0.018
Resection (gross total removal vs. biopsy or resection)	0.628	0.402–0.980	0.040	0.807	0.508–1.282	0.364
Irradiation dosage, per Gy	0.979	0.970–0.987	<0.001	0.979	0.968–0.990	<0.001
Other therapy (additional therapy vs. non-additional therapy)	0.415	0.261–0.660	<0.001	0.605	0.336–1.092	0.095
Secondary versus primary glioblastoma	0.598	0.305–1.172	0.134	*	*	*
<i>IDH1</i> mutated versus non-mutated	0.273	1.137–0.543	<0.001	0.209	0.093–0.471	<0.001

KPS Karnofsky performance score, *IDH1* isocitrate dehydrogenase 1, HR hazard ratio, CI confidence interval

* Not included in multivariate analysis




Fig. 1 Adjusted survival curves comparing *IDH1*^{R132} mutated and non-mutated glioblastoma patients. Constructed with the use of multi-variable Cox proportional hazards regression, and adjusted for age, Karnofsky performance score, irradiation and additional treatments

section were selected to measure the enzyme activity. Of note, no activity was observed in regions of necrosis.

Next, we correlated the mutational status of *IDH1* with the quantitative data of NADP⁺-dependent IDH activity (Fig. 3a). The presence of *IDH1* mutations was inversely associated with NADP⁺-dependent IDH activity

($P = 0.001$). The individual NADP⁺-dependent IDH activity values are shown in Fig. 3b. Activity varied strongly among tumors; nevertheless, we observed a two-fold reduction in activity.

As a control, the activity of NADP⁺-dependent G6PDH and NAD⁺-dependent IDH was assessed on serial sections of the same samples. *IDH1* mutations were not associated with NADP⁺-dependent G6PDH activity ($P = 0.60$; Fig. 3c) or with NAD⁺-dependent IDH activity ($P = 0.639$; Fig. 3d), indicating that the correlation with *IDH1* mutations is specific for the NADP⁺-dependent IDH activity.

Table 3 shows that IDH had the largest capacity to generate NADPH in normal brain, wild-type glioblastoma and *IDH1*-mutated glioblastoma. Sixty-five % of the NADPH-producing capacity was provided by IDH. The total NADPH-generating capacity was significantly reduced by 38% by the *IDH1*^{R132} mutation ($P = 0.02$; Table 3). For this experiment, a subset of 13 wild-type tumor samples, 13 tumor samples mutated at *IDH1*^{R132} and 5 samples of normal brain were used. Again, the difference between NADP⁺-dependent IDH activity in non-mutated and mutated tumor samples was significant ($P = 0.01$).

The combination of our findings indicates that *IDH1* mutations are associated with improved survival in glioblastoma and that *IDH1* mutated glioblastoma samples have a lower NADPH-producing capacity, thus suggesting

Fig. 2 NADP⁺-dependent IDH activity in *IDH1*^{R132} non-mutated ($n = 36$) and mutated ($n = 15$) tumors. NADP⁺-dependent IDH activity staining of *IDH1*^{R132} non-mutated **a** and mutated **c** glioblastoma cryostat sections. The amount of blue color (nitro BT-formazan) directly reflects NADP⁺-dependent IDH activity (production of NADPH). H&E staining of serial sections of non-mutated **(b)** and mutated **(d)** samples




Fig. 3 Capacity (maximum velocity; V_{\max}) of dehydrogenases in IDH^{R132} non-mutated and mutated tumors expressed as micromoles NADPH or NADH produced/ml of tissue/min, \pm SD. NADP⁺-dependent IDH activity (a); individual values of NADP⁺-dependent IDH activity (b); NADP⁺-dependent G6PD activity (c); NAD⁺-dependent IDH activity (d)




Table 3 Capacity (maximum velocity; V_{\max}) of NADPH-generating dehydrogenases as determined by image analysis in cryostat sections of non-cancerous brain ($n = 5$), wild-type glioblastoma ($n = 13$) and

IDH-mutated glioblastoma ($n = 13$) and expressed as mean micromoles NADPH generated per milliliters of tissue per min \pm SD [7, 28, 29]

	Normal brain	Wild-type glioblastoma	IDH1-mutated glioblastoma
IDH	1.95 \pm 1.17	3.82 \pm 2.03	2.02 \pm 1.73
G6PDH	0.99 \pm 0.16	1.59 \pm 0.76	1.12 \pm 0.74
6PGDH	0.10 \pm 0.05	0.23 \pm 0.16	0.20 \pm 0.10
MDH	0.30 \pm 0.12	0.19 \pm 0.17	0.23 \pm 0.20
H6PDH	0.02 \pm 0.01	0.09 \pm 0.05	0.04 \pm 0.02
Total capacity	3.34 \pm 1.12	5.88 \pm 2.73	3.65 \pm 2.29

IDH isocitrate dehydrogenase, *G6PDH* glucose-6-phosphate dehydrogenase, *6PGDH* 6-phosphogluconate dehydrogenase, *MDH* malate dehydrogenase, *H6PDH* hexose-6-phosphate dehydrogenase

that diminished NADPH formation correlates with improved survival. In 43 glioblastoma patients, lower NADP⁺-dependent IDH activity appeared to be correlated with improved survival. However, the correlation was not significant (hazard ratio: 1.108 μ moles NADPH produced/ml of tissue/min; CI 0.880–1.394; $P = 0.38$), probably due to the limited size of the examined cohort.

Discussion

A high percentage of human gliomas has been found to harbour mutations in the metabolic enzyme *IDH1*. We confirm here the previously reported findings that

IDH1 mutations are predominantly found in secondary glioblastoma and in younger patients (Table 1) [5, 10, 19, 24, 25, 32, 34] and that *IDH1* mutations correlate independently with improved prognosis in glioblastoma patients (Table 2; Fig. 1).

When *IDH1* and *IDH2* mutations are ectopically (over)expressed in human cells, they reduce NADP⁺-dependent IDH activity [12, 36]. Thus far, nothing was known about the effect of *IDH1* and *IDH2* mutations on IDH activity in glioblastoma in situ. In order to shed light on the functional effects of *IDH1* mutations, we exploited an integrated approach to measure NADP⁺-dependent IDH activity in situ on brain tumor samples. Using this strategy, we showed for the first time that *IDH1*^{R132} mutations are

associated with on average a twofold decreased NADP⁺-dependent IDH activity in the tumors. As both IDH1 and IDH2 use NADP⁺ as a co-factor, we cannot differentiate between the activity of IDH1 and IDH2. However, considering that we did not observe any *IDH2* somatic mutations in the samples that we analyzed, our work indicates that the reduced NADP⁺-dependent IDH activity is associated with the presence of *IDH1* mutations. The loss of NADPH production capacity by mutated IDH1 is considerable (38%) because NADP-dependent IDH activity represents 65% of the total capacity (Table 3). As mutated IDH1 consumes rather than produces NADPH [8], the loss of NADPH for scavenging oxygen radicals and detoxification is likely even more profound. It may explain prolonged survival of glioblastoma patients with the IDH1 mutation. NADPH is necessary for biosynthetic processes such as lipogenesis and for detoxification [14]. Low levels of cytoplasmic NADPH result in impaired reduction of glutathione (GSH), which is a major scavenger of oxygen radicals in the cells. Diminished levels of GSH thus lead to oxidative stress that can ultimately cause DNA damage and induce apoptosis [13, 16]. Oxidative stress is generally increased by irradiation and chemotherapy [20], and we speculate that it is further enhanced in the presence of *IDH1* mutations. Thus, tumors with the mutation may be less resistant to irradiation and chemotherapy which explains the prolonged survival of patients with mutated tumors. Low levels of cytoplasmic NADPH also affect the thioredoxin system, a family of small redox active proteins that are kept in reduced form by the NADPH-dependent thioredoxin reductase and help to maintain the redox state in cells [4]. Thioredoxins are frequently overexpressed in cancer and play a role in resistance to irradiation and chemotherapy like reduced GSH.

In conclusion, we have shown that *IDH1*^{R132} mutations correlate with diminished NADPH production in situ in glioblastoma and provide an independent survival advantage to glioblastoma patients. This may be explained by a reduced capacity to produce NADPH in combination with NADPH consumption by mutated IDH1 instead of NADPH production by wild-type IDH1. Our data suggest that NADPH metabolism may be therapeutically exploited in gliomas.

Acknowledgments We thank L. Oegema and N. Schmidt for their help with the metabolic mapping and image analysis, A. Zwinderman and N. van Geloven for help with statistical analyses, and F. DiNiccolantonio, J. Reijneveld and S. Thorlacius for critical reading of an earlier version of the manuscript. This work was supported by grants from the Italian Association for Cancer Research (AIRC: AB), Italian Ministry of Health, Regione Piemonte (AB), Italian Ministry of University and Research, CRT Progetto Alfieri (AB), and Association for International Cancer Research (AICR-UK: AB) and EU FP6 contract 037297 (AB). F.B. is supported by a Netherlands Genomic Initiative Fellowship.

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References

1. Aghili M, Zahedi F, Rafiee E (2009) Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review. *J Neurooncol* 91:233–236
2. Balakrishnan A, Bleeker FE, Lamba S et al (2007) Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma. *Cancer Res* 67:3545–3550
3. Balss J, Meyer J, Mueller W et al (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. *Acta Neuropathol* 116:597–602
4. Biaglow JE, Miller RA (2005) The thioredoxin reductase/thioredoxin system. *Cancer Biol Ther* 4:6–13
5. Bleeker FE, Lamba S, Leenstra S et al (2009) IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. *Hum Mutat* 30:7–11
6. Butcher RG, Van Noorden CJF (1985) Reaction rate studies of glucose-6-phosphate dehydrogenase activity in sections of rat liver using four tetrazolium salts. *Histochem J* 17:993–1008
7. Chieco P, Jonker A, Melchiorri C et al (1994) A user's guide for avoiding errors in absorbance image cytometry: a review with original experimental observations. *Histochem J* 26:1–19
8. Dang L, White DW, Gross S et al (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. *Nature* 462:739–747
9. Geisbrecht BV, Gould SJ (1999) The human PICD gene encodes a cytoplasmic and peroxisomal NADP(+)-dependent isocitrate dehydrogenase. *J Biol Chem* 274:30527–30533
10. Hartmann C, Meyer J, Balss J et al (2009) Type and frequency of *IDH1* and *IDH2* mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. *Acta Neuropathol* 118:469–474
11. Hughes JM, Groot AJ, Van der Groep P et al (2009) Active HIF-1 in the normal human retina. *J Histochem Cytochem* PMID 19901273
12. Ichimura K, Pearson DM, Kocalkowski S et al (2009) *IDH1* mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. *Neuro Oncol* 11:341–347
13. Kim SY, Lee SM, Tak JK et al (2007) Regulation of singlet oxygen-induced apoptosis by cytosolic NADP(+)-dependent isocitrate dehydrogenase. *Mol Cell Biochem* 302:27–34
14. Koehler A, Van Noorden CJF (2003) Reduced nicotinamide adenine dinucleotide phosphate and the higher incidence of pollution-induced liver cancer in female flounder. *Environ Toxicol Chem* 22:2703–2710
15. Koshland DE Jr, Walsh K, LaPorte DC (1985) Sensitivity of metabolic fluxes to covalent control. *Curr Top Cell Regul* 27:13–22
16. Lee SM, Park SY, Shin SW et al (2009) Silencing of cytosolic NADP(+)-dependent isocitrate dehydrogenase by small interfering RNA enhances the sensitivity of HeLa cells toward staurosporine. *Free Radic Res* 43:165–173
17. Mardis ER, Ding L, Doolong DJ et al (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome. *N Engl J Med* 361:1058–1066
18. Margittai E, Banhegyi G (2008) Isocitrate dehydrogenase: a NADPH-generating enzyme in the lumen of the endoplasmic reticulum. *Arch Biochem Biophys* 471:184–190

19. Nobusawa S, Watanabe T, Kleihues P et al (2009) *IDH1* mutations as molecular signature and predictive factor of secondary glioblastomas. *Clin Cancer Res* 15:6002–6007
20. Ozben T (2007) Oxidative stress and apoptosis: impact on cancer therapy. *J Pharm Sci* 96:2181–2196
21. Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. *Science* 321:1807–1812
22. Pollard PJ, Ratcliffe PJ (2009) Puzzling patterns of predisposition. *Science* 324:192–194
23. Rasband WS (2009) ImageJ. <http://rsbweb.nih.gov/ij/>
24. Sanson M, Marie Y, Paris S et al (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. *J Clin Oncol* 27:4150–4154
25. Sonoda Y, Kumabe T, Nakamura T et al (2009) Analysis of *IDH1* and *IDH2* mutations in Japanese glioma patients. *Cancer Sci* 100:1996–1998
26. Stoward P, Van Noorden CJF (1991) Histochemical methods for dehydrogenases. Churchill–Livingstone, Edinburgh
27. Thompson CB (2009) Metabolic enzymes as oncogenes or tumor suppressors. *N Engl J Med* 360:813–815
28. Van Noorden CJF, Butcher RG (1991) Quantitative enzyme histochemistry. Churchill–Livingstone, Edinburgh
29. Van Noorden CJF, Frederiks WM (1992) Enzyme histochemistry. A laboratory manual of current methods. Oxford Science Publications, Oxford
30. Van Noorden CJF (2009) Metabolic mapping by enzyme histochemistry in living animals, tissues and cells. *J Physiol Pharmacol* 60(Suppl 4):125–129
31. Vischer N, Nastase S (2009) ObjectJ. <http://simon.bio.uva.nl/>
32. Watanabe T, Nobusawa S, Kleihues P et al (2009) *IDH1* mutations are early events in the development of astrocytomas and oligodendrogliomas. *Am J Pathol* 174:1149–1153
33. Watanabe T, Vital A, Nobusawa S et al (2009) Selective acquisition of *IDH1* R132C mutations in astrocytomas associated with Li-Fraumeni syndrome. *Acta Neuropathol* 117:653–656
34. Weller M, Felsberg J, Hartmann C et al (2009) Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German glioma network. *J Clin Oncol* 27:5743–5750
35. Xu X, Zhao J, Xu Z et al (2004) Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity. *J Biol Chem* 279:33946–33957
36. Yan H, Parsons DW, Jin G et al (2009) *IDH1* and *IDH2* mutations in gliomas. *N Engl J Med* 360:765–773
37. Ying W (2008) NAD⁺/NADH and NADP⁺/NADPH in cellular functions and cell death: regulation and biological consequences. *Antioxid Redox Signal* 10:179–206
38. Zhao S, Lin Y, Xu W et al (2009) Glioma-derived mutations in *IDH1* dominantly inhibit *IDH1* catalytic activity and induce HIF-1 α . *Science* 324:261–265